Compare Fox Corp Class A (FOXA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

FOXA trades at $62.70, up 1.0% today, with a bearish technical signal but strong fundamentals including a P/E of 16.55 and net income margin of 9.84%. Recent earnings beats and a consensus analyst price target of $72.00 suggest upside potential, though the pending Roku acquisition faces DOJ scrutiny, adding regulatory risk. Cash flow improved in 2025, but a projected net cash outflow in 2026 warrants monitoring.

The outlook is mixed: solid profitability and analyst support contrast with technical weakness and acquisition uncertainty. Investors may find value if the Roku deal proceeds smoothly, but regulatory delays or integration challenges pose significant downside risks to near-term performance.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.